

Appl. No. 09/607,602
Atty. Docket No. 8141
Amdt. Dated January 12, 2007
Response to Office Action Dated July 18, 2006
Customer Number 27752

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. *(Canceled)*
2. *(Currently Amended)* A method for promoting whole body health in human and other animal subjects having or at risk of developing an oral cavity pathogen-induced systemic disease comprising topically administering to the oral cavity of subjects in need of treatment thereof, a topical oral composition comprising a pharmaceutically acceptable oral carrier and an amount of a H2-antagonist effective to decrease systemic blood levels of C-reactive protein and apolipoprotein B, which are elevated in said subjects in response ~~mediate systemic host reaction to the presence of said oral cavity pathogens in the subject's oral cavity and to decrease thereby decreasing risk~~ factors for said systemic disease.
2. *(Original)* A method for promoting whole body health in human and other animal subjects according to Claim 2, wherein said composition is in a form selected from the group consisting of a mouthrinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge, dental implement, and a pet care product.
3. *(Original)* A method for promoting whole body health in human and other animal subjects according to Claim 2, wherein said H-2 antagonist is selected from the group consisting of cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-25368 (SKF-94482), BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634,

Appl. No. 09/607,602
Att. Docket No. 8141
Amdt. Dated January 12, 2007
Response to Office Action Dated July 18, 2006
Customer Number 27752

bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728, HB-408, and mixtures thereof.

4. *(Canceled)*

5. *(Canceled)*

7. *(Original)* A method for promoting whole body health in human and other animal subjects according to Claim 2, wherein said composition topically administered to said subjects comprises an additional therapeutic active selected from the group consisting of antimicrobial/antiplaque agents, biofilm inhibiting agents, antibiotics; analgesics and local anesthetic agents; dentinal desensitizing agents; odor masking agents; and mixtures thereof.